世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032


Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases)... もっと見る

 

 

出版社 出版年月 電子版価格 納期 ページ数 言語
Market Research Future
マーケットリサーチフューチャー (MRFR)
2025年2月14日 US$4,950
シングルユーザライセンス(PDF/印刷不可)
ライセンス・価格情報
注文方法はこちら
通常2-3営業日以内 215 英語

 

Summary

Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032

Market Overview
The biosimilars market is predicted to expand from 11.39 (USD Billion) in 2023 to 41.6 (USD Billion) by 2032. The Biosimilars Market CAGR (growth rate) is anticipated to be approximately 15.49% over the forecast period.
Several main drivers are driving the biosimilars industry, including an increase in the prevalence of chronic diseases and a growing need for inexpensive biologic treatments. As healthcare costs continue to grow, biosimilars provide a cost-effective alternative that can improve patient access to critical therapies. Regulatory reforms and developments in manufacturing processes also contribute to market growth by streamlining the approval process and improving product quality. The transition to value-based care models stresses the necessity of low-cost treatment choices, making biosimilars a crucial component of the healthcare ecosystem.

Market segment insights
The Biosimilars Market is expanding rapidly, notably in the Type category, which includes key medicinal goods such as monoclonal antibodies, insulin, erythropoietin, and growth hormones.
The Biosimilars Market is growing rapidly, with a valuation of 11.39 USD billion in 2023 and a forecast revenue of 41.6 USD billion by 2032. This expansion can be attributable to rising demand for more cost-effective treatment alternatives across a variety of therapeutic areas, particularly in the Application segment.
In the Biosimilars Market, the End Use segment is critical to establishing the landscape of healthcare delivery. By 2023, the total market is predicted to be worth 11.39 billion USD, indicating the industry's strong expansion. Hospitals are a prominent player in this area, as they increasingly use biosimilars to reduce treatment costs and improve patient outcomes. Clinics also make a substantial contribution, catering to a vast patient population seeking cost-effective solutions in a variety of therapeutic fields.

The Biosimilars sector was assessed at 11.39 USD billion in 2023, with strong growth projected in the following years as the sector transitions to advanced manufacturing technologies. Within the Manufacturing Process category, technologies such as Recombinant DNA Technology and Hybridoma Technology play critical roles in biosimilar development.

Regional insights
The Biosimilars Market is expected to grow rapidly across all regions, with North America, Europe, APAC, South America, and MEA contributing significantly to revenue. North America maintains a majority stake worth 5.0 USD billion in 2023 and is expected to grow to 17.5 USD billion by 2032, proving its dominance in the business due to a robust healthcare infrastructure and increased demand for cost-effective therapies. Europe follows closely, with a valuation of 3.5 USD billion in 2023 and a projected growth rate of 13.0 USD billion, owing to favorable regulations and increased acceptance of biosimilars among healthcare professionals.

The APAC region is rising, with a value of 2.0 USD billion in 2023 and an expected growth to 8.0 USD billion, demonstrating promise due to growing patient populations and increased healthcare investments. South America and MEA are smaller markets, with valuations of 0.7 USD billion and 0.19 USD billion respectively in 2023, but they offer chances for growth as healthcare systems expand and access to biosimilars improves. The overall Biosimilars Market data reflects a dynamic growth landscape influenced by regional healthcare policies, patient access to medications, and the economic benefits associated with biosimilar therapies.

Key players
Key Companies in the Biosimilars Market Include Zydus Cadila, Eli Lilly, Samsung Bioepis, GSK, AbbVie, Boehringer Ingelheim, Teva Pharmaceutical Industries, Celltrion, Fresenius Kabi, Amgen, Reddy's Laboratories, Mylan, Sandoz, Pfizer, and Novartis.




ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. MARKET OVERVIEW
1.2. KEY FINDINGS
1.3. MARKET SEGMENTATION
1.4. COMPETITIVE LANDSCAPE
1.5. CHALLENGES AND OPPORTUNITIES
1.6. FUTURE OUTLOOK
2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. SCOPE OF THE STUDY
2.2.1. RESEARCH OBJECTIVE
2.2.2. ASSUMPTION
2.2.3. LIMITATIONS
3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING MODEL
3.6. MARKET SIZE ESTIMATION
3.6.1. BOTTOM-UP APPROACH
3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION
4. MARKET DYNAMICS
4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES
5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.2. PORTER'S FIVE FORCES ANALYSIS
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. MARKET IMPACT ANALYSIS
5.3.2. REGIONAL IMPACT
5.3.3. OPPORTUNITY AND THREAT ANALYSIS
6. BIOSIMILARS MARKET, BY TYPE (USD BILLION)
6.1. MONOCLONAL ANTIBODIES
6.2. INSULIN
6.3. ERYTHROPOIETIN
6.4. GROWTH HORMONES
7. BIOSIMILARS MARKET, BY APPLICATION (USD BILLION)
7.1. ONCOLOGY
7.2. DIABETES
7.3. AUTOIMMUNE DISEASES
7.4. CHRONIC INFLAMMATORY DISEASES
8. BIOSIMILARS MARKET, BY END USE (USD BILLION)
8.1. HOSPITALS
8.2. CLINICS
8.3. HOMECARE
8.4. RESEARCH INSTITUTIONS
9. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS (USD BILLION)
9.1. RECOMBINANT DNA TECHNOLOGY
9.2. HYBRIDOMA TECHNOLOGY
9.3. TRANSGENIC TECHNOLOGY
10. BIOSIMILARS MARKET, BY REGIONAL (USD BILLION)
10.1. NORTH AMERICA
10.1.1. US
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. UK
10.2.3. FRANCE
10.2.4. RUSSIA
10.2.5. ITALY
10.2.6. SPAIN
10.2.7. REST OF EUROPE
10.3. APAC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. MALAYSIA
10.3.6. THAILAND
10.3.7. INDONESIA
10.3.8. REST OF APAC
10.4. SOUTH AMERICA
10.4.1. BRAZIL
10.4.2. MEXICO
10.4.3. ARGENTINA
10.4.4. REST OF SOUTH AMERICA
10.5. MEA
10.5.1. GCC COUNTRIES
10.5.2. SOUTH AFRICA
10.5.3. REST OF MEA
11. COMPETITIVE LANDSCAPE
11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE BIOSIMILARS MARKET
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOSIMILARS MARKET
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
11.7.2. MERGER & ACQUISITIONS
11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
11.8.1. SALES AND OPERATING INCOME
11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023
12. COMPANY PROFILES
12.1. ZYDUS CADILA
12.1.1. FINANCIAL OVERVIEW
12.1.2. PRODUCTS OFFERED
12.1.3. KEY DEVELOPMENTS
12.1.4. SWOT ANALYSIS
12.1.5. KEY STRATEGIES
12.2. ELI LILLY
12.2.1. FINANCIAL OVERVIEW
12.2.2. PRODUCTS OFFERED
12.2.3. KEY DEVELOPMENTS
12.2.4. SWOT ANALYSIS
12.2.5. KEY STRATEGIES
12.3. SAMSUNG BIOEPIS
12.3.1. FINANCIAL OVERVIEW
12.3.2. PRODUCTS OFFERED
12.3.3. KEY DEVELOPMENTS
12.3.4. SWOT ANALYSIS
12.3.5. KEY STRATEGIES
12.4. GSK
12.4.1. FINANCIAL OVERVIEW
12.4.2. PRODUCTS OFFERED
12.4.3. KEY DEVELOPMENTS
12.4.4. SWOT ANALYSIS
12.4.5. KEY STRATEGIES
12.5. ABBVIE
12.5.1. FINANCIAL OVERVIEW
12.5.2. PRODUCTS OFFERED
12.5.3. KEY DEVELOPMENTS
12.5.4. SWOT ANALYSIS
12.5.5. KEY STRATEGIES
12.6. BOEHRINGER INGELHEIM
12.6.1. FINANCIAL OVERVIEW
12.6.2. PRODUCTS OFFERED
12.6.3. KEY DEVELOPMENTS
12.6.4. SWOT ANALYSIS
12.6.5. KEY STRATEGIES
12.7. TEVA PHARMACEUTICAL INDUSTRIES
12.7.1. FINANCIAL OVERVIEW
12.7.2. PRODUCTS OFFERED
12.7.3. KEY DEVELOPMENTS
12.7.4. SWOT ANALYSIS
12.7.5. KEY STRATEGIES
12.8. CELLTRION
12.8.1. FINANCIAL OVERVIEW
12.8.2. PRODUCTS OFFERED
12.8.3. KEY DEVELOPMENTS
12.8.4. SWOT ANALYSIS
12.8.5. KEY STRATEGIES
12.9. FRESENIUS KABI
12.9.1. FINANCIAL OVERVIEW
12.9.2. PRODUCTS OFFERED
12.9.3. KEY DEVELOPMENTS
12.9.4. SWOT ANALYSIS
12.9.5. KEY STRATEGIES
12.10. AMGEN
12.10.1. FINANCIAL OVERVIEW
12.10.2. PRODUCTS OFFERED
12.10.3. KEY DEVELOPMENTS
12.10.4. SWOT ANALYSIS
12.10.5. KEY STRATEGIES
12.11. REDDY'S LABORATORIES
12.11.1. FINANCIAL OVERVIEW
12.11.2. PRODUCTS OFFERED
12.11.3. KEY DEVELOPMENTS
12.11.4. SWOT ANALYSIS
12.11.5. KEY STRATEGIES
12.12. MYLAN
12.12.1. FINANCIAL OVERVIEW
12.12.2. PRODUCTS OFFERED
12.12.3. KEY DEVELOPMENTS
12.12.4. SWOT ANALYSIS
12.12.5. KEY STRATEGIES
12.13. SANDOZ
12.13.1. FINANCIAL OVERVIEW
12.13.2. PRODUCTS OFFERED
12.13.3. KEY DEVELOPMENTS
12.13.4. SWOT ANALYSIS
12.13.5. KEY STRATEGIES
12.14. PFIZER
12.14.1. FINANCIAL OVERVIEW
12.14.2. PRODUCTS OFFERED
12.14.3. KEY DEVELOPMENTS
12.14.4. SWOT ANALYSIS
12.14.5. KEY STRATEGIES
12.15. NOVARTIS
12.15.1. FINANCIAL OVERVIEW
12.15.2. PRODUCTS OFFERED
12.15.3. KEY DEVELOPMENTS
12.15.4. SWOT ANALYSIS
12.15.5. KEY STRATEGIES
13. APPENDIX
13.1. REFERENCES
13.2. RELATED REPORTS

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Market Research Future社の医療分野での最新刊レポート

本レポートと同じKEY WORD(biosimilars)の最新刊レポート


よくあるご質問


Market Research Future社はどのような調査会社ですか?


マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。   下記分野については、分野毎に専... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/08 10:26

148.77 円

163.31 円

192.60 円

ページTOPに戻る